As I see it: transparency

Share this article:
So how's it workin' out for ya—all this new Obama transparency stuff?

Apart from a new web page explaining itself in lay terms, at FDA there is no more transparency than there was two years ago—which has provoked New York Democrat Maurice Hinchey, a vociferous FDA critic in the Bush years, to introduce the FDA Improvement Act of 2010.

Its aim is to end what Hinchey sees as a financial link and inappropriately close relationship between the drug industry and FDA. It would also improve the agency's post-market drug safety operations, impose fees on drug and medical device company advertising to better monitor ads, and eliminate conflicts of interest on advisory committees.

Most of these objectives could be accomplished in other ways by optimal public transparency, opening the agency to cleansing sunlight from vigilant watchdogs and the media—something that isn't going to happen. Hinchey's bill would do it the old-fashioned way—directing user-fee moneys to be deposited in the US Treasury general fund instead of FDA's account, and providing mandatory congressional funding levels for the agency.

Thus, he says, FDA would be fully funded by and accountable to taxpayers. He says the agency currently depends on drug and device company money.

“For far too long,” Hinchey says, “FDA has been structured in a way that benefits the drug companies and undermines the agency's ability to properly regulate these products.”

Widening public discontent with government combined with suspicion about what user fees really buy—or, more importantly, are perceived to buy—could give this bill some impetus.

James G. Dickinson is editor of Dickinson's FDA Webview (fdaweb.com)
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications